404
Views
12
CrossRef citations to date
0
Altmetric
Letters to the Editor

A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia

, , , , , , , , , , & show all
Pages 728-730 | Received 28 Apr 2015, Accepted 20 Jul 2015, Published online: 05 Oct 2015
Supplemental material

GLAL-2015-0417-File012.pdf

Download PDF (1.2 MB)

GLAL-2015-0417-File011.pdf

Download PDF (1.2 MB)

GLAL-2015-0417-File010.pdf

Download PDF (1.2 MB)

GLAL-2015-0417-File009.pdf

Download PDF (1.2 MB)

GLAL-2015-0417-File008.pdf

Download PDF (1.2 MB)

GLAL-2015-0417-File007.pdf

Download PDF (1.2 MB)

GLAL-2015-0417-File006.pdf

Download PDF (1.2 MB)

GLAL-2015-0417-File005.pdf

Download PDF (1.2 MB)

GLAL-2015-0417-File004.pdf

Download PDF (1.2 MB)

GLAL-2015-0417-File003.pdf

Download PDF (1.2 MB)

GLAL-2015-0417-File002.pdf

Download PDF (1.2 MB)

GLAL-2015-0417-File001.pdf

Download PDF (1.2 MB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.